Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; ...

Kamada begins patient enrolment in an investigator-initiated clinical trial of Cytogam to prevent cytomegalovirus in kidney transplantation: Rehovot, Israel Thursday, November 6, ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $ (0.2) billion and GAAP EPS of $ (0.51) Improves 2025 ...

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...

Learn more about whether Moderna, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Viral infections, including HIV and influenza, are associated with an increased risk of cardiovascular disease, including coronary heart disease and stroke.

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today ...

Moderna posted a loss of 51 cents a share for the third quarter, down from a profit of 3 cents last year, but narrower than ...

"It is well recognized that human papillomavirus (HPV), hepatitis B virus, and other viruses can cause cancer; however, the ...